The American Society of Nuclear Cardiology explored some key points included in the 2025 Medicare Physician Fee Schedule proposed rule.

Inspired by nature and funded by the European Research Council, a group of scientists and engineers thinks its new research could represent a significant breakthrough in TAVR care.

The Society of Cardiovascular Computed Tomography has developed a new expert consensus document designed to get physicians on the same page when discussing this growing technology. 

Emily Lau, MD, a women's health expert with Massachusetts General Hospital, thinks major changes are needed in how we diagnose CVD in women. "Our guidelines need to be more precise and offer sex-specific recommendations," she says.

Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.

Researchers explored more than 100,000 online reviews, using AI to learn as much as possible about what drives patients to give their cardiologist a positive or negative rating.

Care teams gained significant momentum in the early days of TAVR. Now, however, they are being used to address a wide variety of cardiovascular concerns. 

According to the new proposal, the 2025 conversion factor would be $32.36, down approximately 2.8% from 2024. SCAI, MGMA and other groups have already stepped forward with warnings that these cuts could do significant damage to patient care.